OR WAIT null SECS
“Patients want to see an improvement. They want a drug that obviously is efficacious and safe, where the side effects are low,” says David Staskin, MD.
In this video, David Staskin, MD, discusses the takeaways associated with the findings from the study, “Vibegron for the treatment of patients with dry overactive bladder: A subgroup analysis from the EMPOWUR trial,” presented at the 2021 American Urological Association annual meeting. Staskin is a director of the Center for Male and Female Pelvic Health and associate professor of urology at Tufts University, Boston, Massachusetts.